OTONOMY INC (OTIC) Stock Price & Overview
NASDAQ:OTIC • US68906L1052
Current stock price
The current stock price of OTIC is 0.077 USD. Today OTIC is down by -11.19%. In the past month the price decreased by -29.87%. In the past year, price decreased by -96.65%.
OTIC Key Statistics
- Market Cap
- 4.401M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.77
- Dividend Yield
- N/A
OTIC Stock Performance
OTIC Stock Chart
OTIC Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to OTIC. When comparing the yearly performance of all stocks, OTIC is a bad performer in the overall market: 98.25% of all stocks are doing better.
OTIC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OTIC. OTIC has a bad profitability rating. Also its financial health evaluation is rather negative.
OTIC Earnings
OTIC Forecast & Estimates
9 analysts have analysed OTIC and the average price target is 9.18 USD. This implies a price increase of 11822.08% is expected in the next year compared to the current price of 0.077.
For the next year, analysts expect an EPS growth of 3.04% and a revenue growth -100% for OTIC
OTIC Groups
Sector & Classification
OTIC Financial Highlights
Over the last trailing twelve months OTIC reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS increased by 4.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.01 |
OTIC Ownership
OTIC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.31 | 900.456B | ||
| JNJ | JOHNSON & JOHNSON | 20.96 | 587.99B | ||
| MRK | MERCK & CO. INC. | 23.35 | 298.764B | ||
| PFE | PFIZER INC | 9.56 | 162.403B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.75 | 125.711B | ||
| ZTS | ZOETIS INC | 16.57 | 49.512B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 27.972B | ||
| VTRS | VIATRIS INC | 5.43 | 15.693B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.98 | 11.495B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.787B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.274B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.606B | ||
| CORT | CORCEPT THERAPEUTICS INC | 50.81 | 4.465B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OTIC
Company Profile
Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
Company Info
IPO: 2014-08-13
OTONOMY INC
5626 Oberlin Drive, Suite 100
San Diego CALIFORNIA 92121 US
CEO: David A. Weber
Employees: 51
Phone: 18587687823.0
OTONOMY INC / OTIC FAQ
What does OTIC do?
Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
Can you provide the latest stock price for OTONOMY INC?
The current stock price of OTIC is 0.077 USD. The price decreased by -11.19% in the last trading session.
Does OTONOMY INC pay dividends?
OTIC does not pay a dividend.
What is the ChartMill rating of OTONOMY INC stock?
OTIC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists OTIC stock?
OTIC stock is listed on the Nasdaq exchange.
What is OTONOMY INC worth?
OTONOMY INC (OTIC) has a market capitalization of 4.40M USD. This makes OTIC a Nano Cap stock.
When does OTONOMY INC (OTIC) report earnings?
OTONOMY INC (OTIC) will report earnings on 2023-02-27.